Fundraising Fox
Abzena
Cambridge, US · Founded 2014 · United Kingdom corporation · 438 employees on LinkedIn · 5 known investors
Find your way into Abzena
Sign up to see every warm intro you have to Abzena
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Abzena team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Abzena is an integrated CDMO and CRO providing end-to-end development and cGMP manufacturing services for complex biologics and bioconjugates, including ADCs, AOCs, bispecifics, and HPAPIs. It serves biotech, academic, and pharmaceutical customers across the drug development lifecycle from discovery through commercial manufacturing.
Founders & leadership
Investors · 5
How we know: Beringea's portfolio page · Not right? Tell us
How we know: BIOSPRING PARTNERS's portfolio page · funding news · abzena.com · Not right? Tell us
How we know: funding news · Not right? Tell us
Also in the syndicate · 1
Reported raises · per SEC filings
Form D private placements$4.3M disclosed across 2 of 4 rounds · 2015–2022
▶$3.6MraisedDec 2015 · 2 investors · BiotechnologyRule 506(b)
- Jim MillsExecutive Officer
- Kenneth CunninghamDirector
- Campbell BunceExecutive Officer
- Nareshkumar JainExecutive Officer
- Gary PierceExecutive Officer
- Anker LundemoseDirector
- Julian SmithExecutive Officer, Director
- William John Edward BurtExecutive Officer, Director
- Leigh PierceExecutive Officer
- Nigel PitchfordDirector
- Sally WatermanExecutive Officer
- Matthew BakerExecutive Officer
- Peter GrantDirector
- Anthony BramptonDirector
- Offering amount
- $3.6M
- Amount sold
- $3.6M
- First sale
- Dec 2015
- Incorporated
- Corporation, United Kingdom, 2014
- Federal exemptions
- 06b
▶$700KraisedSep 2015 · 7 investors · BiotechnologyRule 506(b)
- Nigel PitchfordDirector
- Leigh PierceExecutive Officer
- William John Edward BurtExecutive Officer, Director
- Kenneth CunninghamDirector
- Julian SmithExecutive Officer, Director
- Anthony BramptonDirector
- Anker LundemoseDirector
- Peter GrantDirector
- Matthew BakerExecutive Officer
- Offering amount
- $700K
- Amount sold
- $700K
- First sale
- Sep 2015
- Incorporated
- Corporation, United Kingdom, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
3 people who came through Abzena went on to found or lead other companies.
Related companies · 2
Companies working in the same space as Abzena.
In the news
Frequently asked questions
- What does Abzena do?
- Abzena is an integrated CDMO and CRO providing end-to-end development and cGMP manufacturing services for complex biologics and bioconjugates, including ADCs, AOCs, bispecifics, and HPAPIs. It serves biotech, academic, and pharmaceutical customers across the drug development lifecycle from discovery through commercial manufacturing.
- Who are Abzena's investors?
- Abzena's investors include Beringea, BIOSPRING PARTNERS, WCAS, Welsh, Carson, Anderson & Stowe.
- How much funding has Abzena raised?
- Abzena has disclosed $4.3M raised across 2 of its 4 known rounds.
- Where is Abzena headquartered?
- Abzena is headquartered in Cambridge, US.